Fig. 2

Results of CSF biomarkers of neurodegeneration and synaptic dysfunction. Mean (s.e.m.) absolute (pg/mL) change from baseline to week 24 CSF sampling is shown. The difference between neflamapimod treatment and placebo was significant for T-tau [difference (95% CI): −18.8 (−35.8, −1.8); P=0.031] and p-tau₁₈₁ [−2.0 (−3.6, −0.5); P=0.012], with a trend for neurogranin [−21.0 (−43.6, 1.6); P=0.068.  N=68 for placebo and N=62 for neflamapimod for A, B, E and F.  N=70 for placebo and N=63 for neflmapimod for C and D.]